Pharma and BioTech Daily
Pharma & Biotech Daily is a short, AI-generated, human-supervised briefing on what's important in pharma and biotech. Each weekday it condenses key news on pipelines, deals, regulation and strategy into a quick audio update for people who build, run and invest in life sciences. The show is produced by OWITH.ai, a boutique AI & data studio.
Episodes
Ultragenyx's $97M Gene Therapy Breakthrough! | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest advancements and achievements across this dynamic industry, where innovation is reaching new heights and regulatory landscapes are continuously evolving.
In a groundbreaking moment for gene therapy, Ultragenyx has sec
Merck's $1B Melanoma Vaccine Breakthrough | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into recent strides made in scientific research, regulatory landscapes, and market dynamics that are shaping the future of healthcare.
Starting with a significant breakthrough in cancer treatment, Merck & Co. and Moderna have reported pr
Biokin's $275M ADC Success in Phase 3 Trial | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of updates that underscore the dynamism and complexity of these industries, marked by breakthroughs, strategic shifts, and regulatory hurdles.
A notable scientific advancement comes from Biokin Pharma, where their bispecific antibody-dr
AstraZeneca Tagrisso Breakthrough: Phase 3 Success in NSCLC | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of groundbreaking updates that could significantly impact drug development and patient care.
Vera Therapeutics recently announced promising Phase 3 clinical trial results for its monoclonal antibody, Trutakna, in treating immu
FDA Fast-Tracks NASH Drug | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the latest breakthroughs, regulatory updates, and clinical trial results shaping our industry.
Recently, a significant milestone has been achieved in gene therapy. A new study showcases a groundbreaking approach to treating rare genetic
AstraZeneca's Baxfendy Setback: Pricing Woes | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent weeks have showcased a dynamic landscape in these sectors, marked by scientific breakthroughs, regulatory updates, and strategic business decisions that are collectively reshaping the future of drug development and patient care.
AstraZeneca recently faced cha
Akeso's Ivonescimab Wins NSCLC Approval in China | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.
Today, we're diving into a series of compelling stories that underscore the dynamic shifts and groundbreaking progress within the industry.
Recently, Akeso's ivonescimab received a landmark approval for first-line treatment of non-small cell lung cancer (
Bristol Myers Squibb's $2.3B Texas Investment Boosts Jobs | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of drug manufacturing, regulatory affairs, and scientific breakthroughs that are shaping the future of patient care and therapeutic innovation.
Bristol Myers Squibb has made headlines with its substantial $2.3 billion inves
Novo Nordisk & AWS Partner for AI Drug Discovery Breakthrough | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a landscape marked by remarkable scientific breakthroughs, strategic alliances, and regulatory milestones that are shaping the future of healthcare.
Novo Nordisk is making waves with its new partnership with Amazon Web Services, utilizi
Replimune's FDA Win: Tudriqev Approved After 2 Rejections | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode delves into the latest innovations and strategic shifts propelling the industry forward.
A notable dialogue emerging in psychiatric drug development comes from TLDR Biotech's engagement with Shlomi Raz and Ken Belotsky, co-founders of Palom
Moderna mRNA Flu Vaccine Approved by FDA | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of pivotal advancements that underscore the dynamic nature of our industry.
Starting with Moderna, which has recently secured FDA approval for its mRNA-based influenza vaccine, MFLUSIVA. This marks a monumental leap in leverag
Eli Lilly's $23B Q2 Revenue Breaks Records | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate web of scientific advancements, regulatory updates, and strategic maneuvers shaping the industry.
Let's begin with Eli Lilly's impressive financial performance, clocking a record-breaking $23 billion in revenue for Q2 202
Otsuka's Voyxact Shines in Phase 3 Trial | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest scientific advancements, regulatory milestones, and strategic business maneuvers shaping the industry.
One of the standout developments comes from Otsuka with their drug Voyxact, which has shown promising results in s
Supernus & Indivior $2.2B Merger Creates CNS Giant | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into recent transformative events that are shaping this dynamic industry, from strategic mergers to groundbreaking drug approvals.
Starting with the merger between Supernus Pharmaceuticals and Indivior Pharmaceuticals, this all-stock deal valued at $
Replimune's Breakthrough in Cancer Therapy | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent weeks have been a whirlwind of activity in the pharmaceutical and biotech sectors, showcasing significant strides in scientific breakthroughs, regulatory advancements, and strategic industry maneuvers.
Replimune's Vusolimogene Oderparepvec has emerged as
Johnson & Johnson's $785M CAR-T Deal & More | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of events that underscore the dynamic nature of these industries, characterized by scientific advancements, strategic partnerships, and regulatory milestones.
Johnson & Johnson has made headlines with its substantial $785 million up
Biogen Acquires Apellis for Growth | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.
Biogen has made a significant acquisition by purchasing Apellis Pharmaceuticals, a move expected to boost its 2026 revenue guidance with promising growth prospects. This strategic acquisition, along with strong sales from new drugs, enhances Biogen's position i
GlaxoSmithKline's $2.5B Restructuring Near AstraZeneca | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into the latest news shaping these dynamic sectors, exploring strategic corporate maneuvers, groundbreaking scientific advances, and pivotal regulatory changes.
GlaxoSmithKline (GSK) is embarking on a comprehensive restructuring initiative aimed at ac
AstraZeneca's $80B Target Amid Setbacks? | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a wealth of significant advancements and strategic moves shaping the industry landscape.
AstraZeneca is making waves with its steadfast commitment to reaching an $80 billion revenue target by 2030. This ambitious goal is underpinned by
Scribe Therapeutics Raises $129M in IPO | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the latest groundbreaking advancements, strategic corporate maneuvers, and pivotal regulatory updates shaping this dynamic industry landscape.
Starting with some exciting news, Scribe Therapeutics has successfully closed its initial pub
Eli Lilly's Retatrutide: 22.6% Weight Loss in Phase 3! | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most exciting scientific breakthroughs and regulatory developments that are shaping the future of healthcare.
Eli Lilly's retatrutide, a promising small molecule GLP-1 receptor agonist, has achieved significant results
Repligen Buys BioLife for $1.5B | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of significant breakthroughs and strategic moves reshaping the industry landscape.
Repligen Corporation's recent decision to acquire BioLife Solutions for $1.5 billion marks a pivotal moment in the cell therapy sector. Bi
Bristol Myers & NVIDIA's $1.5B AI Deal: Game Changer? | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent advancements in these sectors highlight a fascinating intersection of technology and medicine, underscoring a push towards innovation that promises to reshape healthcare delivery.
Bristol Myers Squibb has expanded its collaboration with NVIDIA, aiming to crea
Samsung Biologics' $1.8B Peptide Expansion | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're navigating through a myriad of transformative advancements reshaping the industry. From artificial intelligence-driven research breakthroughs to strategic acquisitions in emerging therapeutic areas, these developments are setting new benchmarks in d
Jasper Merges with Kira for $292M | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of industry-shaping events, reflecting the ever-evolving landscape of drug development, regulatory challenges, and strategic maneuvers.
In a significant move within the sector, Jasper Therapeutics has merged with Kira Pharmaceuticals, a
Merck's $5B Lipfendra FDA Approval Revolutionizes Cholesterol | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to forge ahead, making significant strides in scientific advancements, regulatory approvals, and strategic business developments. These moves are reshaping the landscape of drug development and patient care.
Starting with Merck & Co.'
Veradermics' $2B Hair Loss Market Move with Oral Minoxidil | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the latest advancements shaping the future of drug discovery and patient care.
Veradermics is making significant strides with its oral minoxidil formulation aimed at addressing female pattern hair loss. The mid-stage clinical trial results have ana
Biogen's $1.5B Deal & FDA Approval for Alzheimer's Drug | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into an array of groundbreaking advancements and strategic movements reshaping the landscape of healthcare and medicine.
Recent strides in Alzheimer's research have highlighted Biogen's promising Phase 2 clinical trial results for
Pfizer & Merck's $3B Bladder Cancer Breakthrough | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest news and insights that are shaping the landscape of patient care and drug development.
The U.S. FDA has expanded the label for Pfizer and Astellas' Padcev, in combination with Merck's Keytruda, to include all muscle-invasive
Sanofi's FDA Approval: $160M Boost for Sarclisa in Cancer Care | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative updates and strategic shifts within the industry, reflecting both remarkable progress and inherent challenges.
Sanofi's recent achievement marks a significant milestone in oncology with the FDA approval o
Ipsen's Dysport Hits Phase 3 Milestone vs. Botox | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and challenges shaping the landscape of these dynamic sectors.
Starting with Ipsen’s Dysport, which has made notable strides in its Phase 3 trials for migraine prevention. The trials covered both episodic and
Vera Therapeutics' Trutakna Gets FDA Nod for IgA Nephropathy | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events shaping our industry, starting with a significant regulatory milestone.
Vera Therapeutics recently achieved FDA accelerated approval for Trutakna, a groundbreaking treatment for IgA nephropathy. This approval no
Vertex Acquires Crinetics for $10B | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that showcase the dynamic nature of this industry.
In a landmark development, Vertex Pharmaceuticals has made headlines with its acquisition of Crinetics Pharmaceuticals for a staggering $10 billion. This
Novartis' $1.1B Myricx Acquisition Boosts ADC Pipeline | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The first quarter of 2026 has brought a wave of significant changes and advancements in the industry, marked by crucial regulatory updates, strategic acquisitions, and shifts in the competitive landscape.
A pressing issue for many companies is the looming patent cli
FDA Accelerated Approval: New Drug for Breast Cancer | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we dive into some significant advancements reshaping the industry.
Starting with a breakthrough in gene therapy, researchers have announced promising results from a Phase 1 clinical trial targeting a rare genetic disorder known as Leber congenital amaurosis. T
Roche's Divarasib Surpasses Amgen in Trials | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of remarkable advancements and strategic maneuvers that are shaping the future of drug development and patient care.
Starting with Roche's breakthrough in oncology, their small molecule inhibitor, Divarasib, has shown promising res
Orca Bio's Tregzi Wins FDA Approval for GVHD | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a wave of exciting advancements and strategic movements shaping the landscape of this ever-evolving industry.
Starting with a significant breakthrough in cell therapy, the FDA has granted approval to Orca Bio's Tregzi, a novel trea
FDA Fast-Tracks Eli Lilly & Regeneron | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant advancements and strategic shifts reshaping the industry landscape.
To begin, the U.S. Food and Drug Administration has taken a noteworthy step by selecting key industry players, including Eli Lilly, Regeneron, F
Ipsen Buys Kartos for $1.75B | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of the pharmaceutical and biotech sectors, where significant scientific advancements, regulatory shifts, and strategic business maneuvers are reshaping patient care and therapeutic approaches.
A pivotal moment recently unfo
Replimune's RP1 Resubmission to FDA: Will It Finally Pass? | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the landscape of this dynamic industry.
Replimune has made headlines with the resubmission of its oncolytic virus-based immunotherapy, RP1, to the U.S. Food and Drug Administration for treatin
Merck's $11.3B Bio-Techne Acquisition | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the dynamic shifts and breakthroughs shaping the industry, from major acquisitions to groundbreaking scientific advancements.
Merck KGaA has made headlines with its bold $11.3 billion acquisition of Bio-Techne Corporation. This marks Merck’s most s
Eli Lilly's $1.9B Abbisko Partnership Boosts Cancer R&D | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of impactful developments shaping the future of medical innovation and patient care. The landscape of pharmaceutical and biotech industries is currently experiencing notable shifts driven by scientific advancements, regulatory updates, a
Carsgen's $2T Satricabtagene Approval Milestone | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into the latest scientific breakthroughs, regulatory advancements, and strategic industry movements that are shaping the landscape of healthcare innovation.
Kicking off with significant strides in drug approvals, Carsgen Therapeutics has ma
Carsgen's CAR-T Breakthrough in China for Solid Tumors | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of groundbreaking advancements and strategic shifts that are shaping the future of healthcare.
In a remarkable development from China, Carsgen has achieved approval for the world's first CAR-T therapy targeting solid tumors. This th
FDA Approves Alzheimer's Drug Amid Debate | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most exciting stories shaping the industry right now.
Let's start with a groundbreaking advancement in gene therapy. Researchers have achieved a significant milestone by successfully using CRISPR technology to treat a r
FDA Approves Utebzi, Biogen Acquires Raythera for $1B | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to evolve, with significant scientific advancements, regulatory updates, and strategic business moves shaping the landscape. Let's delve into these developments, starting with some key insights from oncology.
In the realm of oncology, min
Eli Lilly's $65B M&A Surge & FDA's Drug Import Approval | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a rapidly evolving landscape marked by significant scientific breakthroughs, regulatory shifts, and strategic business maneuvers.
The pharmaceutical and biotech sectors are buzzing with renewed vigor, as evidenced by an impressive resurgence in
Intellia's 89% Success in Phase 3 CRISPR Trial | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and strategic maneuvers transforming the industry landscape.
Intellia Therapeutics has made remarkable progress with lonvoguran ziclumeran, achieving an 89% reduction in attack rates in its Phase 3 trial for h
Novartis' $23M RNA Breakthrough & Tavneos FDA Battle | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore a series of pivotal advancements and challenges shaping the industry landscape—ranging from scientific breakthroughs to regulatory maneuvers, all underscoring the sector's dynamic evolution.
Novartis has made headlines with its investi
Takeda's Zasocitinib Beats Sotyktu in Phase 3 Trial | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of remarkable updates that highlight the dynamic evolution of drug development, regulatory landscapes, and industry strategies.
Takeda has made waves with its TYK2 inhibitor, Zasocitinib, which recently outperformed Bristol Mye
Pfizer CEO Rethinks Germany Investments Amid Reform Concerns | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The pharmaceutical and biotech industries are undergoing significant transformations, driven by scientific advancements, regulatory changes, and strategic investments. These developments are shaping the landscape of drug development and patient care in profound ways.
Merck & Gilead's HIV Pill Breakthrough: Phase 3 Success! | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is one of constant evolution, characterized by scientific advancements, strategic mergers, and regulatory maneuvers that shape the future of healthcare.
In a significant scientific breakthrough, Merck & Co. and Gilead Sciences h
Eli Lilly's Retatrutide Breakthrough: 30.3% Weight Loss Success | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of groundbreaking advancements and strategic movements reshaping the landscape of drug development and patient care.
Eli Lilly's retatrutide has emerged as a significant breakthrough in obesity treatment, demonstrating a
Pfizer & Chai AI Breakthrough: $1.675B Gilead Deal | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements shaping the landscape of our industry. As technology continues to redefine traditional paradigms, the collaboration between Pfizer and Chai Discovery exemplifies this trend. By harnessing artificial intelligen
Eli Lilly & Boehringer Cut $1B+ Investments in Germany | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.
Today, we delve into the evolving landscape of the pharmaceutical and biotechnology industries, where scientific advancements, regulatory updates, and strategic business decisions are reshaping the future. A significant development in this dynamic arena is the strat
Legend Biotech's CAR T-Cell Breakthrough: 100% Response Rate | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most significant advancements in scientific research, clinical trials, and regulatory landscapes within the industry. These developments are shaping the future of patient care and drug development significantly.
Starting wit
Moderna-Merck Combo Cuts Melanoma Risk by 49% | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of groundbreaking advancements and strategic maneuvers reshaping the landscape of drug development and patient care.
In recent news, Moderna and Merck & Co. have reported substantial progress in cancer treatment with their Phase 2b t
Akeso's Ivonescimab Shows 34% Death Risk Cut at ASCO | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of fascinating advancements in the industry, each with significant implications for future patient care and drug development.
At the recent American Society of Clinical Oncology (ASCO) 2026 conference, Akeso's ivonescimab, a pioneer
Pfizer's $10B Innovent Deal Boosts Cancer Drugs | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore a landscape teeming with strategic partnerships, groundbreaking clinical trial results, regulatory shifts, and innovative therapeutic approaches that are redefining patient care and drug development.
Pfizer's monumental $10 billion col
Eli Lilly's Zepbound Coverage Restored! Breaking News | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent updates offer a fascinating glimpse into an industry marked by dynamic shifts and groundbreaking advancements, each promising to reshape the future of healthcare. Let's delve into some of the most notable developments that are capturing attention across t
Outlook Therapeutics Wins FDA Appeal for $1.3B Deal | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of events shaping the industry, ranging from regulatory hurdles to strategic acquisitions and scientific breakthroughs.
A significant milestone has been achieved by Outlook Therapeutics with its product Lytenava (bevacizumab),
Gilead's Hepcludex FDA Approval Marks Milestone | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries continues to evolve with significant scientific advancements, regulatory breakthroughs, and strategic maneuvers that are reshaping drug development and patient care.
One of the noteworthy developments is the U.S. FDA's recent a
Recommended
FemTech Focus
Not Too Sensitive - Empowering Highly Sensitive People (HSPs) To Own Their Sensitivity
Mother Daughter Relationship Show
Skin Deep MDs with Dr. Mamina Turegano, Dr. Lindsey Zubritsky and Dr. Jenny Liu
girl talk 🎧🫧
Booked, Blonde & Busy w/ Olivia Ponton
LOVE SOMEONE with Delilah
Classical Christian Education
Veritas Vox - The Voice of Classical Christian Education
Enjoy Teaching Again | Elementary, Teacher Burnout, Student Behavior, SEL, Classroom Management
Entrepreneur Kids Legacy Show - Family Motivation, Business Boss Babies, Inspirational Speakers and Healthy fun food
McKinsey on Consumer and Retail
